Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel.Invest with Confidence: Follow ...

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

Patients with squamous cell carcinoma of the head and neck were randomly assigned to receive either intensity-modulated radiotherapy with weekly cetuximab or radiotherapy alone.

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics ...

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes to treatment.Cutaneous ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...